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Methicillin-resistant
Staphylococcus
aureus Toxic Shock
Syndrome
To the Editor: Toxic shock syn-
drome (TSS), which can be life threat-
ening, is defined by clinical and labo-
ratory evidence of fever, rash, desqua-
mation, hypotension, and multiple
organ failure caused by Staphylococ-
cus aureus toxins. TSS caused
by methicillin-resistant S. aureus
(MRSA) strains has been found
extensively in Japan (1), rarely in the
United States (2), and, thus far, not in
Europe.
We report a case of TSS due to an
MRSA strain that produced a TSS
toxin 1 (TSST-1). A 54-year-old
woman was admitted to the emer-
gency ward of Brugmann University
Hospital, Brussels, with a 2-day histo-
ry of myalgia, diarrhea, and vomiting.
She had undergone surgery for a
palate neoplasia 2 months earlier, and
again 2 weeks earlier, in another hos-
pital. After the second operation, she
had been treated for a local scar infec-
tion with amoxicillin–clavulanic acid
for 1 week.
On physical examination, the
patient was conscious, tachypneic,
pale, and sweating. Her temperature
was 38.2°C and her blood pressure
was 70/50 mm Hg. Abdominal exami-
nation findings were normal. The cuta-
neous operative wound was red and
swollen. Laboratory results included
the following: leukocyte count
19,830/mm³ with 97% polynuclear
neutrophils, platelets 90,000/mm³, cre-
atinine 2.1 mg/dL, bicarbonate 13
mEq/L, cyclic AMP receptor protein
43.7 ng/mL, creatine kinase 514 U/L.
Cultures of blood, stool, and urine
samples were negative for microbial
agents. Puncture of the wound
released 12 mL of pus; culture of the
pus sample yielded an MRSA strain
harboring a TSST-1 gene, detected by
multiplex polymerase chain reaction
as previously described (3).
By molecular typing, the strain
belonged to the epidemic MRSA
pulsed-field gel electrophoresis clone
G10 and carried the staphylococcal
chromosome cassette mec (SCCmec)
type II. This clone belongs to the
sequence type (ST) 5-SCCmec II
clone, formerly named “New-
York/Japan clone,” which has been
associated with neonatal TSS–like
exanthematous disease in Japanese
hospitals (4–6). This epidemic clone,
which is widely disseminated in the
United States, Japan, and Europe, has
been found in 12% of Belgian hospi-
tals during a national survey conduct-
ed in 2001 (6).
The treatment included aggressive
intravenous fluid resuscitation,
administration of dopamine, and
antimicrobial agent therapy with
teicoplamin and clindamycin. The
treatment outcome was favorable. On
the second day, a diffuse cutaneous
macular rash appeared. The acute
renal failure and the biological abnor-
malities resolved. On the fifth day, the
patient was transferred back to the
hospital where she had undergone sur-
gery; extensive peeling then devel-
oped on both of the patient’s hands. 
Our patient met the criteria of TSS:
she had fever, rash, desquamation,
hypotension, vomiting, diarrhea,
myalgias, elevated creatine kinase,
acute renal failure, and thrombocy-
topenia. The diagnosis of staphylo-
coccal TSS was confirmed by bacteri-
ologic results.
Although TSST-1 production by
MRSA strains has been described in
Europe (7), this case is the first of TSS
due to TSST-1–producing MRSA in
Europe. Recently Nathalie van der
Mee-Marquet et al. (8) described the
first case of neonatal TSS–like exan-
thematous disease due to a MRSA
strain containing the TSST-1 gene in
Europe. They emphasized the risk of
emergence of neonatal toxic shock
syndrome–like exanthematous dis-
ease outside Japan.
We would also like to emphasize
the rising risk of TSS due to virulent
MRSA strains outside Japan and par-
ticularly in Europe. The usual recom-
mendations for the treatment of
staphylococcal TSS do not consider
this possibility and consist of a β-lac-
tamase–resistant anti-staphylococcal
agent and clindamycin in some cases
(to decrease the synthesis of TSST-1)
(9–11).
We immediately treated our patient
with teicoplanin and clindamycin
because we suspected a nosocomial
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infection with S. aureus, possibly
MRSA. The possibility of MRSA
must be considered when initiating
antimicrobial agents to treat TSS.
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Are SARS
Superspreaders
Cloud Adults?
To the Editor: The primary mode
of transmission of severe acute respi-
ratory syndrome (SARS) appears to
be through exposure to respiratory
droplets and direct contact with
patients and their contaminated envi-
ronment. However, in summarizing
their experiences during the SARS
outbreaks in Toronto and Taiwan,
McDonald et al. (1) note that certain
persons were very efficient at trans-
mitting SARS coronavirus (SARS-
CoV), and that in certain settings
these so-called “superspreaders”
played a crucial role in the epidemic.
Airborne transmission by aerosols
may have occurred in many of these
cases. The same observation has been
made by others (2–4), but the causes
of these superspreading events and
the reasons for the variable communi-
cability of SARS-CoV are still
unclear. Possible explanations include
specific host characteristics (e.g.,
altered immune status, underlying dis-
eases), higher level of virus shedding,
or environmental factors (1–3). 
We hypothesize that superspread-
ing events might be caused by coin-
fection with other respiratory viruses.
Such a mechanism has been identified
in the transmission of Staphylococcus
aureus. Eichenwald et al. (5) showed
that newborns whose noses are colo-
nized with this bacterium disperse
considerable amounts of airborne S.
aureus and become highly contagious
(i.e., superspreaders) after infection
with a respiratory virus (e.g., aden-
ovirus or echovirus). These babies
caused explosive S. aureus outbreaks
in nurseries. Because they are literally
surrounded by clouds of bacteria, they
were called “cloud babies” (5). We
have shown that the same mechanism
also occurs in certain adult nasal car-
riers of S. aureus (“cloud adults”)
(6,7). Reports indicate that viral infec-
tions of the upper respiratory tract
facilitate the transmission of other
bacteria, including Streptococcus
pneumoniae,  S. pyogenes,  Haemo-
philus influenzae, and Neisseria
meningitidis (8). Moreover, super-
spreading events have also been
reported in outbreaks of viral diseases
such as Ebola hemorrhagic fever and
rubella (3). 
Some observations suggest that
coinfection with other respiratory
viruses might cause superspreading
events with airborne transmission of
SARS-CoV. First, other viral
pathogens, including human metap-
neumovirus, have been detected
together with SARS-CoV in some
patients with SARS (4). Second, few
patients with SARS are superspread-
ers, and upper respiratory symptoms
such as rhinorrhea and sore throat are a
relatively uncommon manifestation of
SARS (with prevalences of 14% and
16%, respectively) (4). Thus, some
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